BioSpace News Archive

Novavax, Inc. (Nasdaq: NVAX), today announced that Swissmedic, the Swiss Agency for Therapeutic Products, has expanded its temporary authorization of Nuvaxovid™ (NVX-CoV2373).

Mersana Therapeutics, Inc. announced that on September 1, 2022, an authorized sub-committee of the Compensation Committee of the Board of Directors of Mersana granted inducement awards, consisting of stock options to purchase an aggregate of 25,575 shares of its common stock and restricted stock unit awards to acquire an aggregate of 64,950 shares of its common stock, to 9 new employees whose employment commenced in August 2022.

Inari Medical, Inc. announced that its management team will host the Company’s first Analyst and Investor Day on Thursday, September 15, 2022 at its headquarters in Irvine, CA.

Provention Bio, Inc. announced that the Company granted stock options to two non-executive employees to purchase an aggregate of 38,000 shares of common stock.

10x Genomics, Inc. (Nasdaq: TXG), a life sciences leader focused on mastering biology to advance human health, today announced the company will be participating in the upcoming Morgan Stanley 20th Annual Global Healthcare Conference in New York, New York.

Amgen (NASDAQ:AMGN) will present at Wells Fargo’s 2022 Global Healthcare Conference at 9:45 a.m. ET on Thursday, September 8, 2022.

Akebia Therapeutics, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted six newly-hired employees options to purchase an aggregate of 27,000 shares of Akebia’s common stock on August 31, 2022, as inducements material to each such employee entering into employment with Akebia.

JacobioPharma announced that the company has dosed the first non-small cell lung cancer patient with KRAS G12C and STK11 co-mutation in the Phase IIa trial of KRAS G12C inhibitor JAB-21822 in China.

Microbot Medical Inc. announced, as part of the preparation for its anticipated U.S. Food and Drug Administration and CE Mark submissions, that it recently shipped multiple LIBERTY Robotic System devices to a market-leading research laboratory to conduct the Company’s GLP pre-clinical trial.

KalVista Pharmaceuticals, Inc., announced that the compensation committee of KalVista’s board of directors granted five newly-hired employees inducement options to purchase an aggregate of 18,000 shares of KalVista common stock on September 1, 2022 as inducements material to each employee entering into employment with KalVista.